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Cardiovascular medicine trainees hear their faculty utter
his phrase often. Let me tell you how I decide when, how,
r whether to prescribe statins, or to order some type of
oninvasive test, or to send a patient to the catheterization
aboratory, or to recommend medical or surgical revascular-
zation. Trainees amuse themselves by noting the enormous
ariability in how their faculty fills in the blank; for some
cenarios, there seem to be as many approaches as
ardiologists!
What may be amusing, and confusing, for trainees is, in
act, the basis of serious health care and research policy
ebates. Enormous variations in practice have been well
ocumented for many cardiovascular procedures (1). Pa-
ients in some parts of the U.S. are 10 times as likely as
imilar patients elsewhere to be referred for stress imaging
r coronary revascularization (2,3). Furthermore, there
eems to be little association between the patterns of
ardiovascular practice and cardiovascular health: people
ho live in regions where more cardiovascular tests and
rocedures are performed do not live longer or have fewer
ardiac events (4). Health policy experts cite practice vari-
tion as symptomatic of uncertainty, waste, inefficiency, and
oor performance of the health care enterprise (5,6).
Why is there so much practice variation? While it may be
asy to dismiss it as “the art of medicine,” the main causes
re uncertainty and lost translation. Uncertainty, because for
any common clinical scenarios, definitive evidence dem-
nstrating that 1 approach is better than another does not
xist. We do not know, for example, if a patient with
ew-onset chest pain will have a different outcome if
eferred for 1 type of noninvasive test as compared to
nother (7). Even when definitive guidelines are dissemi-
rom the Division of Prevention and Population Sciences, National Heart, Lung, andf
lood Institute, National Institutes of Health, Bethesda, Maryland.
Manuscript received October 31, 2008, accepted November 5, 2008.ated, evidence-based practices are often slow to be widely
ncorporated into routine practice.
A number of health policy experts and professional
roups have identified comparative effectiveness research
CER) as a solution to the problem of unjustified practice
ariation (8,9). The Congressional Budget Office defines
ER as “a rigorous evaluation of the impact of different
ptions that are available for treating a given medicine
ondition for a particular set of patients” (10). CER may
ompare competing drugs (e.g., atorvastatin vs. simvasta-
in), competing modalities (e.g., antiarrhythmic drugs vs.
efibrillators, or stents vs. coronary bypass grafting, medical
herapy vs. revascularization), or may primarily focus on the
osts and benefits of specific options. CER includes tradi-
ional randomized trials, pragmatic trials, cost-effectiveness
nalyses, and observational studies.
During the past few years, as health care costs seem to
piral out of control, CER has taken center stage on Capitol
ill. As of this writing, at least 10 bills have been intro-
uced into the 100th U.S. Congress that directly address
ER. Senator Max Baucus (D-MT) introduced the Com-
arative Effectiveness Research Act of 2008, which proposes
o establish a private, nonprofit corporation called the
ealth Care Comparative Effectiveness Research Institute
11). The Institute would be governed by a Board with
epresentatives from multiple sectors, would be charged
ith identifying national priorities for CER, and would be
llowed to enter into contracts with different entities for
onducting research.
While the phrase “comparative effectiveness research” is
elatively new, CER has long been a high priority for the
ardiovascular community and for the National Health, Lung,
nd Blood Institute (NHLBI). Over many decades, the
HLBI has funded or co-funded numerous landmark com-
arative trials that have had a major impact on practice. Just a
ew examples, nearly all well known to practicing cardiovascular
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March 24, 2009:1084–6 Comparative Effectiveness Researchpecialists, include the CASS (Coronary Artery Surgery
tudy), the ALLHAT (Antihypertensive and Lipid-Lowering
reatment to Prevent Heart Attack Trial) (12), the WHI
Women’s Health Initiative) (13), and the SCD-HeFT (Sud-
en Cardiac Death in Heart Failure Trial) (14) studies. More
ecent and ongoing major NHLBI-funded comparative trials
nclude the OAT (Occluded Artery Trial) (15) and the
CCORD (Action to Control Cardiovascular Risk in Diabe-
es) (16) studies. A major trial now in planning is the SPRINT
Systolic Blood Pressure Intervention Trial) study, which will
ompare aggressive and conservative management strategies
or prevention of complications of systolic hypertension.
The NHLBI’s interest in CER is not limited to random-
zed trials. The Cardiovascular Research Network (CVRN)
s taking advantage of a rich electronic data structure
overing 10 million patients to analyze 3 important
herapeutic questions: 1) How is hypertension recognized,
reated, and controlled within community practices? 2) How is
arfarin used to prevent adverse thrombotic events in atrial
brillation and venous thromboembolism? 3) What are the
linical characteristics, outcomes, and costs for patients
eceiving implantable defibrillators for primary prevention
f sudden cardiac death (17)? The CVRN represents a
iable example of Paul Ellwood’s call for “outcomes man-
gement” in his 1988 Shattuck Lecture (18).
The NHLBI’s commitment to CER is longstanding and
as recently explicitly recognized as a critical component of
ur Strategic Plan (19), which states that we hold it as a high
riority “to generate an improved understanding of the pro-
esses involved in translating research into practice . . . [and to]
valuate the risks, benefits, and costs of diagnostic tests and
reatments in representative populations and settings.” We
re pleased that the health policy community and the public
t large have a renewed interest in CER. We are eager to be
ctive not only in initiating, catalyzing, and supporting
ER but also in participating in the national policy debate
bout how CER is best prioritized and directed.
The national CER debate includes a number of critical
uestions, all of which are relevant for the cardiovascular
ommunity. What should be the relative roles of random-
zed controlled trials versus observational studies? Given
ome of the well-known observational failures, such as the
mpact of hormone replacement therapy on outcomes, can
bservational studies ever be trusted for developing guide-
ines or public health policies? How should CER priorities
e established, even within a field like cardiovascular med-
cine? Should diagnostic tests, like computed tomography
ngiography, also be considered a target for CER just
ike more conventional therapeutic strategies? Should
overnment-sponsored CER primarily be directed by exist-
ng federal agencies (like the National Institutes of Health,
he Agency for Healthcare Research and Quality, and the
eterans Administration), or should a separate entity be
stablished? How can optimal coordination be achieved
mong existing federal agencies as well as between federal
gencies and private sector research sponsors? Can research oethodologies be improved,
aking it possible to perform
arge scale trials at substantially
ower costs or to generate more
rustworthy outcomes from ob-
ervational studies? Should cost
ffectiveness be part of CER, or
hould it be explicitly divorced
rom it, given political sensitiv-
ties (8,20)?
The NHLBI is, and plans to be, an active player in
ddressing all of these questions. We are funding work that
ttempts to reconcile differences between randomized trials
nd observational studies; as an example, parallel analyses are
eing performed of the WHI trials, observational studies, and
urses Health Study (21). Nonetheless, because of multiple
bad experiences” with ultimately debunked observational
ndings, we recognize that controlled trials must remain the
old standard for evidence, with observational studies pri-
arily functioning for hypothesis generation and extension
f trial findings to routine care. Using our Strategic Plan
19) as a guide, we are actively engaged in ongoing dialogues
ith investigators, clinicians, professional societies, commu-
ity groups, and other government agencies to define those
reas of uncertainty where high-quality CER is most likely
o have a major impact on public health and clinical practice.
e are particularly excited about expanding CER beyond
raditional therapeutics; this past summer, we held a work-
hop on CER opportunities in diagnostic imaging, which is
ow 1 of the most rapidly growing technologies within the
edicare program. We have explicitly recognized the im-
ortance of cost, as our Strategic Plan recognizes as a critical
hallenge the need “to identify cost-effective approaches to
revention, diagnosis, and treatment” (19).
The NHLBI also recognizes that high-quality CER is
nly of value if it is incorporated into routine practice. We
ave a longstanding history of synthesizing the literature
nd generating practice guidelines for primary prevention of
ascular disease, including management of hypertension,
besity, and hypercholesterolemia. We are now preparing
pdated guidelines in these specific areas, as well as engag-
ng in an ambitious effort to write integrated guidelines that
ill provide coherent, cohesive recommendations for all
ife-style and medical approaches to primary prevention. We
ook forward to working with clinicians, academic leaders,
nd professional societies to assure rapid and widespread
mplementation of these guidelines.
Cardiovascular medicine is at a crossroads. On the one
and, the NHLBI and the cardiovascular community have
long, proud tradition of initiating and performing out-
tanding CER that has led to strong evidence-based guide-
ines and dramatic improvements in clinical outcomes. On
he other hand, cardiovascular medicine is in the crosshairs
f critics who decry widespread variations in practice, failure
Abbreviations
and Acronyms
CER  comparative
effectiveness research
CVRN  Cardiovascular
Research Network
NHLBI  National Heart,
Lung, and Blood Institutef physicians to adhere to guidelines, and promotion of
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Comparative Effectiveness Research March 24, 2009:1084–6xpensive diagnostic technologies in the absence of any
vidence of better patient or public health.
As we work closely with our cardiovascular colleagues and
ith the public, the NHLBI sees CER as a critically
mportant tool to render obsolete the phrase “Let me tell
ou how I like to ______.”
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